Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Evaluate Vantage's coverage of the virtual AACR 2021 congress.